DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Learn more

CORMEDIX INC. TO PRESENT AT THE NEEDHAM ANNUAL HEALTHCARE CONFERENCE

Berkeley Heights, NJ – March 27, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the Needham 23rd Annual Healthcare Conference, being held virtually on April 8 – 11, 2024. 

Needham 23rd Annual Healthcare Conference
Date: Monday, April 8, 2024
Time: 11:00 a.m. EDT
Format: Fireside Chat
Webcast: Click here

A replay of the fireside chat will also be available in the “Events and Presentations” page on the investor relations portion of the Company’s website at: www.cormedix.com 

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix anticipates the commercial launch of DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024, pending a timely implementation of TDAPA. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations.  For more information visit: www.cormedix.com. 

 

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com 
(617) 430-7576